A
Arnulf Ferlitsch
Researcher at Medical University of Vienna
Publications - 165
Citations - 5723
Arnulf Ferlitsch is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cirrhosis & Portal hypertension. The author has an hindex of 37, co-authored 158 publications receiving 4606 citations. Previous affiliations of Arnulf Ferlitsch include University of Vienna & St John of God Health Care.
Papers
More filters
Journal ArticleDOI
Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.
Mattias Mandorfer,Simona Bota,Philipp Schwabl,Theresa Bucsics,Nikolaus Pfisterer,Matthias Kruzik,Michael Hagmann,Alexander Blacky,Arnulf Ferlitsch,Wolfgang Sieghart,Michael Trauner,Markus Peck-Radosavljevic,Thomas Reiberger +12 more
TL;DR: Among patients with cirrhosis and SBP, NSBBs increase the proportion who are hemodynamically compromised, time of hospitalization, and risks for hepatorenal syndrome and acute kidney injury, and they also reduce transplant-free survival.
Journal ArticleDOI
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.
Thomas Reiberger,Arnulf Ferlitsch,Berit A. Payer,Mattias Mandorfer,B. Heinisch,Hubert Hayden,Frank Lammert,Michael Trauner,Markus Peck-Radosavljevic,Harald Vogelsang +9 more
TL;DR: NSBB treatment ameliorates gastroduodenal/intestinal permeability and reduces bacterial translocation partially independent of their hemodynamic effects on portal pressure, which may contribute to a reduced risk of variceal bleeding.
Journal ArticleDOI
Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt
Bernhard Angermayr,Manfred Cejna,F Karnel,Michael Gschwantler,Franz Koenig,Johann Pidlich,Helmuth Mendel,Ludwig Pichler,M. Wichlas,A. Kreil,M. Schmid,Arnulf Ferlitsch,E Lipinski,Harald Brunner,Johannes Lammer,Peter Ferenci,Alfred Gangl,Markus Peck-Radosavljevic +17 more
TL;DR: Although MELD was the primary predictor of overall survival in multivariate analysis, c statistics showed that both scores can be used for patients undergoing TIPS with equal accuracy, and there seems little reason to replace the well established Child-Pugh score.
Journal ArticleDOI
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol
Thomas Reiberger,G. Ulbrich,Arnulf Ferlitsch,Berit A. Payer,Philipp Schwabl,Matthias Pinter,B. Heinisch,Michael Trauner,Ludwig Kramer,Markus Peck-Radosavljevic,Vienna Hepatic Hemodynamic Lab +10 more
TL;DR: Using carvedilol for primary prophylaxis a substantial proportion of non-responders to propranolol can achieve a haemodynamic response, which is associated with improved outcome with regard to prevention of variceal bleeding, hepatic decompensation and death.
Journal ArticleDOI
Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension
Mattias Mandorfer,Karin Kozbial,Philipp Schwabl,C Freissmuth,Remy Schwarzer,R Stern,David Chromy,Albert Friedrich Stättermayer,Thomas Reiberger,Sandra Beinhardt,Wolfgang Sieghart,Michael Trauner,Harald Hofer,Arnulf Ferlitsch,Peter Ferenci,Markus Peck-Radosavljevic +15 more
TL;DR: SVR to IFN-free therapies might ameliorate portal hypertension across all BL HVPG strata, however, changes inHVPG seemed to be more heterogeneous among patients with BL HvPG of ⩾16mmHg and a HV PG decrease was less likely in patients with more advanced liver dysfunction.